Amended Securities Registration (section 12(b)) (8-a12b/a)
December 21 2021 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A/A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
INMUNE BIO INC.
(Exact name of registrant as specified in its charter)
Nevada
|
|
47-5205835
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
225 NE Mizner Blvd., Suite 640
Boca Raton, Florida 33432
|
|
92037
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Securities to be registered pursuant to Section
12(b) of the Act:
Title of each class
to be so registered
|
|
Name of each exchange on which
each class
is to be registered
|
Preferred Stock Purchase Rights
|
|
The Nasdaq Capital Market
|
If this form relates to the registration of a
class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check
the following box. ☒
If this form relates to the registration of a
class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check
the following box. ☐
If this form relates to the registration of a
class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation
A offering statement file number to which this form relates: Not Applicable
Securities registered pursuant to Section 12(g)
of the Act: None.
Item 1. Description
of Registrant’s Securities to be Registered.
On December 30, 2020, the
Board of Directors (the “Board”) of INmune Bio Inc., a Nevada corporation (the “Company”), approved and adopted
a Rights Agreement, dated as of December 30, 2020 (the “Rights Agreement”), by and between the Company and VStock Transfer,
LLC, as rights agent. Pursuant to the Rights Agreement, the Board declared a dividend of one preferred share purchase right (each, a “Right”)
for each outstanding share of common stock, par value $0.001 per share, of the Company (each, a “Common Share” and, collectively,
the “Common Shares”). The Rights were distributable to stockholders of record as of the close of business on January 11, 2021.
On December 20, 2021, the
Company entered into Amendment No. 1 to the Rights Agreement between the Company and Vstock Transfer, LLC, as rights agent (the “Amendment”),
which amends the Rights Agreement. The Amendment extends the expiration of the Rights Agreement to December 30, 2022.
The description of the Amendment
is qualified in its entirety by reference to the full text of the Amendment, which is attached as Exhibit 4.1 to the Company’s Current
Report on Form 8-K filed on December 21, 2021.
Each Right entitles the
registered holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock,
par value $0.001 per share (each, a “Series A Preferred Shares”), of the Company (the “Preferred Shares”) at a
price of $300 per one one-thousandth of a Series A Preferred Share represented by a Right, subject to adjustment.
The Rights are in all respects
subject to and governed by the provisions of the Rights Agreement, as amended by the Amendment. A copy of the Rights Agreement was attached
as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on December 30, 2020 (the “Original Form 8-K”). The
description of the Rights is incorporated herein by reference to the description set forth in Items 1.01 and 5.03 of the Original Form 8-K and
is qualified in its entirety by reference to the full text of the Rights Agreement, as amended by the Amendment.
Item 2. Exhibits.
See the Exhibit Index below, which is incorporated
by reference herein.
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements
of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereto duly authorized.
|
INMUNE BIO
INC.
|
|
|
Date: December 21, 2021
|
|
|
|
By:
|
/s/
David Moss
|
|
Name:
|
David Moss
|
|
Title:
|
Chief Financial Officer
|
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jun 2024 to Jul 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2023 to Jul 2024